Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy

StatusFinished
Effective start/end date1/12/14 → 30/11/17

Funding

  • Cancer Prevention & Res Inst of TX: $741,414.00
View all
View less

Keywords

  • Biotechnology & Drug Development, Cancer Research, Nanotechnology, Womens Health